HIV and AIDS Clinical Trials

Clinical trials are research studies designed to answer specific questions about the safety and/or effectiveness of drugs, vaccines, other therapies, or new ways of using existing treatments.

Clinical Trials.gov

HIV Infection (over 3,000 studies)

AIDS-related Opportunistic Infections (over 120 studies)

HIV Wasting Syndrome (over 15 studies)

HIV-associated Lipodystrophy (over 20 studies)

Search for a specific HIV drug or condition

Articles on Clinical Trials/Studies:

Emergence of Drug Resistance in HIV Patients on First-line HAART: A Systematic Review of Clinical Trials - 8/26/08

Studies Look at Association between CD4 Cell Count and Cardiovascular Risk in People with HIV - 8/22/08

Women and Men Respond Similarly to Antiretroviral Drugs and Experience Comparable Side Effects: GRACE, M05-730, CASTLE, ARTEM - 8/19/2008

Didanosine (Videx-EC) + Emtricitabine (Emtriva) + Atazanavir (Reyataz) Inferior for Initial HIV Treatment: PEARLS Trial - 8/19/2008

Switching from Other Ritonavir-boosted Protease Inhibitors to Boosted Atazanavir (Reyataz) Did Not Improve Body Fat Accumulation: REAL Study - 8/19/2008

Virological Success with Raltegravir (Isentress) plus Etravirine (Intelence) plus Boosted Darunavir (Prezista) in Patients with Multidrug-resistant HIV: TRIO Trial - 8/15/2008

New NNRTIs IDX899 and RDE806 Appear Safe and Effective in Early Clinical Trials - 8/15/2008

Are Abacavir/lamivudine (Epzicom) and Tenofovir/emtricitabine (Truvada) Equally Effective as NRTI Backbones? ACTG 5202 and HEAT Disagree - 8/12/08

Does Abacavir (Ziagen) Raise Heart Attack Risk? Conflicting Answers from SMART and 54-study Pooled Analysis - 8/12/08

Investigational Next-generation NNRTI Rilpivirine (TMC278) Demonstrates Potent Antiviral Activity at 96 Weeks in Treatment-naive Individuals - 8/08/08

ALVAC-HIV Vaccine Fails to Halt Disease Progression in Patients Undergoing Antiretroviral Treatment Interruption - 7/29/08

Raltegravir (Isentress) with Optimized Background Therapy for Drug-resistant HIV Infection: BENCHMRK 48-week Results - 7/25/08

Gilead Announces Start of Phase III Efficacy Trial of Experimental Integrase Inhibitor Elvitegravir in Treatment-experienced HIV Patients - 7/25/08

NIAID Announces Cancellation of "PAVE 100" Preventive HIV Vaccine Trial - 7/22/08

Efficacy and Safety of Once-daily Boosted Darunavir (Prezista) versus Lopinavir/ritonavir (Kaletra) in Treatment-naive HIV Patients: ARTEMIS Trial - 7/15/08

Idenix Reports Promising Results from Clinical Trial of Experimental NNRTI IDX899 - 6/20/08

NIAID Halts ACTG 5175 Clinical Trial Arm Receiving Once-daily Atazanavir (Reyataz), Emtricitabine (Emtriva), and Didanosine (Videx) - 5/30/08

Worsening Cardiovascular Risk among HIV Positive Individuals in D:A:D Study Has Not Led to an Increase in Heart Attacks - 5/13/08

Interrupting Antiretroviral Therapy Does Not Reduce the Risk of Cardiovascular Disease: Final Results of ACTG 5102 - 4/29/08

HIV Transmission in SMART Study - 3/06/07

SMART Data Confirm Risk of CD4-guided Treatment Interruptions - 12/05/06